Patent · US Active

Vaccination with mRNA-coded antigens

US11975064B2 · kind B2 · utility

0Cited by

5References

24Claims

0Family size

Assignee

CureVac SE · DE

Inventors

Karl-Josef Kallen · Tübingen, DE
Thomas Kramps · Bellinzona, CH
Margit SCHNEE · Konstanz, DE
Benjamin PETSCH · Tübingen, DE
Lothar Stitz · Rottenburg am Neckar, DE

Key dates

Filing date	Mar 7, 2017
Grant date	May 7, 2024
Priority date	—
Expiry date	Mar 7, 2037

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.